BioLineRx licenses compound for neuropathic and inflammatory pain
This article was originally published in Scrip
Executive Summary
Jerusalem-based BioLineRx has signed a worldwide, exclusive licence agreement with Ramot, the technology transfer arm of Tel Aviv University, in order to gain access to the early-stage compound BL-7050, an orally available molecule for neuropathic and inflammatory pain. Financial terms were not disclosed.